Expertise in
8
conditions

Dr. Jennifer Diamond

Oncology
University Of Colorado Hospital
1665 Aurora Ct Fl 2, 
Aurora, CO 
Offers Telehealth
Expertise in
8
conditions
University Of Colorado Hospital
1665 Aurora Ct Fl 2, 
Aurora, CO 

Overview

Jennifer Diamond is an Oncologist in Aurora, Colorado. Dr. Diamond is highly rated in 8 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Triple-Negative Breast Cancer, and Tissue Biopsy.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

University Of Colorado Hospital Authority

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
SelectHealth
  • HMO
  • POS
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

University of Colorado Hospital
1665 Aurora Ct Fl 2, Aurora, CO 80045
Other Locations
University of Colorado Hospital Authority
1635 Aurora Ct, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: TAK-500, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation
Enrollment Status: Terminated
Publish Date: October 01, 2025
Intervention Type: Drug, Biological
Study Drugs: Copanlisib, Pertuzumab, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Enrollment Status: Withdrawn
Publish Date: December 06, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nab-paclitaxel, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)
A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Drug
Study Phase: Phase 1
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors
A Phase 1 Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

83 Total Publications

Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Journal: Gynecologic oncology
Published: May 16, 2025
Similar Doctors
Expertise in
13
conditions
Dr. D Ross
Oncology
Expertise in
13
conditions
Dr. D Ross
Oncology

University Of Colorado Hospital

1665 Aurora Ct Fl 2, 
Aurora, CO 
 (0.4 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

D Ross is an Oncologist in Aurora, Colorado. Dr. Ross is highly rated in 13 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Expertise in
29
conditions
Dr. Breelyn Wilky
Oncology
Expertise in
29
conditions
Dr. Breelyn Wilky
Oncology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Breelyn Wilky is an Oncologist in Aurora, Colorado. Dr. Wilky is highly rated in 29 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Gastrointestinal Stromal Tumor.

Expertise in
31
conditions
Dr. Anthony Elias
Oncology
Expertise in
31
conditions
Dr. Anthony Elias
Oncology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Elias is an Oncologist in Aurora, Colorado. Dr. Elias is highly rated in 31 conditions, according to our data. His top areas of expertise are Breast Cancer, Adult Soft Tissue Sarcoma, Liposarcoma, and Synovial Sarcoma.

Frequently Asked Questions about Dr. Jennifer Diamond

How do I make an appointment with Dr. Jennifer Diamond?

You can book an appointment with Dr. Jennifer Diamond by calling their office at 720-848-0000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer Diamond a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer Diamond is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer Diamond specialize in?

While Dr. Jennifer Diamond is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jennifer Diamond participate in research or clinical trials?

Yes. Dr. Jennifer Diamond has published 83 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Jennifer Diamond's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer Diamond accept my insurance?

Dr. Jennifer Diamond accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-848-0000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Diamond's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile